Seligson & Co Rahastoyhtiö Oyj
SELIGSON & CO OMX HELSINKI 25 EXCHANGE TRADED FUND UCITS ETF: ANNUAL REPORT, BOARD OF THE MANAGEMENT COMPANY AND AUDITOR
SELIGSON & CO OMX HELSINKI 25 EXCHANGE TRADED FUND UCITS ETF: ANNUAL REPORT, BOARD OF THE MANAGEMENT COMPANY AND AUDITOR
Seligson & Co Fund Management Company Plc
STOCK EXCHANGE NOTICE 27 March 2025
SELIGSON & CO OMX HELSINKI 25 EXCHANGE TRADED FUND UCITS ETF: ANNUAL REPORT, BOARD OF THE MANAGEMENT COMPANY AND AUDITOR
The Annual Report of Seligson & Co OMX Helsinki 25 Exchange Traded Fund UCITS ETF, dated 31 December 2024, has been published. The report, which is in Finnish, forms part (pages 44 to 50) of the attached common Annual Report for the Seligson & Co funds. The report and the Auditor's Report are also available at www.seligson.fi/sco/suomi/esitteet/.
The following members were elected to the board of Seligson & Co Fund Management Company Plc at the Annual General Meeting held on 27 March 2025: Ari Kaaro, Samu Anttila and Mikko Vasko. KPMG Plc was chosen as the auditor and CPA Marcus Tötterman as the deputy auditor.
Further information:
Mari Rautanen
email: mari.rautanen@seligson.fi
Phone +358 (0)9 6817 8224
Seligson & Co Fund Management Company Plc
Aleksi Härmä
Managing Director
email: aleksi.harma@seligson.fi
Phone +358 (0)9 6817 8235
Attachments
- Seligson & Co -rahastojen vuosikertomus 31.12.2024
- Seligson&Co Rahastoyhtiö Oyjn rahastot_ttk 2024_2
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
FirstFarms A/S30.3.2025 18:28:10 CEST | Pressemeddelelse
Mulige symptomer på mund- og klovesyge på ét dyr i FirstFarms’ besætning i Slovakiet
FirstFarms A/S30.3.2025 18:28:10 CEST | Press release
Possible symptoms of Foot and Mouth Disease in one animal in FirstFarms’ herd in Slovakia
BYD Energy Storage30.3.2025 18:23:43 CEST | Press release
BYD Energy Storage Launches Chess Plus for C&I Energy Storage in China
Novo Nordisk A/S29.3.2025 19:33:22 CET | Press release
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
Novo Nordisk A/S29.3.2025 15:33:43 CET | Press release
Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom